OTLK — Outlook Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $87.95m
- $113.49m
Annual income statement for Outlook Therapeutics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 38.7 | 51.7 | 64.1 | 53.7 | 71.7 |
| Operating Profit | -38.7 | -51.7 | -64.1 | -53.7 | -71.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -38.5 | -53.2 | -66 | -59 | -75.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -35.2 | -53.2 | -66.1 | -59 | -75.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -35.2 | -53.2 | -66.1 | -59 | -75.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -48.9 | -53.2 | -66.1 | -59 | -75.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -13 | -6.96 | -6.17 | -4.69 | -4.06 |